MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.96
-0.44
-6.88%
After Hours: 5.96 0 0.00% 16:00 09/21 EDT
OPEN
6.32
PREV CLOSE
6.40
HIGH
6.43
LOW
5.94
VOLUME
22.45K
TURNOVER
--
52 WEEK HIGH
30.00
52 WEEK LOW
0.2380
MARKET CAP
97.91M
P/E (TTM)
-0.6934
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
Benzinga · 09/03 11:55
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that Douglas J. Swirsky, President and Chief Executive Officer of
PR Newswire · 09/02 13:30
NeuroBo Pharmaceuticals Q2 EPS $(0.15) Beats $(0.19) Estimate
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.19) by 21.05 percent.
Benzinga · 08/11 19:04
NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes
PR Newswire · 06/16 21:05
NeuroBo Pharmaceuticals to Join Russell 3000 and Microcap Indexes
Benzinga · 06/16 20:10
HC Wainwright & Co. Initiates Coverage On NeuroBo Pharmaceuticals with Buy Rating, Announces Price Target of $20
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $20.
Benzinga · 06/15 11:48
NeuroBo Pharmaceuticals Announces Continuation Of Partial Clinical Hold Of Gemcabene
Benzinga · 05/26 12:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NRBO stock price target is 25.00 with a high estimate of 30.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 27
Institutional Holdings: 4.17M
% Owned: 25.36%
Shares Outstanding: 16.43M
TypeInstitutionsShares
Increased
4
30.41K
New
4
23.37K
Decreased
5
141.74K
Sold Out
3
75.23K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Independent Director
Na Yeon Kim
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
Jeong Gu Kang
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
jeong Gu Kang
Vice President
Nicola Shannon
Other
Mark Versavel
Independent Director
Jason Groves
Independent Director
Tae Heum Jeong
Independent Director
Jeong Gyun Oh
Independent Director
Michael Salsbury
Independent Director
Douglas Swirsky
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average NRBO stock price target is 25.00 with a high estimate of 30.00 and a low estimate of 20.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NRBO
NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.